Skip to main content
Alvotech Holdings S.A logo

Alvotech Holdings S.A — Investor Relations & Filings

Ticker · ALVO ISIN · LU2458332611 LEI · 222100DCZBOWV5DZ8372 LU Manufacturing
Open in API
Filings indexed 913 across all filing types
Latest filing 2026-02-12 Director's Dealing
Country LU Luxembourg
Listing LU ALVO

About Alvotech Holdings S.A

https://www.alvotech.com/

Alvotech is a biotechnology company that specializes in the development and manufacturing of biosimilar medicines for patients worldwide. The company's mission is to improve lives by expanding access to high-quality, affordable biologic medicines. Alvotech operates a fully integrated, end-to-end platform that encompasses the entire process from cell line development through to fill and finish manufacturing. This vertically integrated approach provides control over scale, speed, and quality. For commercialization and registration in global markets, Alvotech leverages strategic partnerships, allowing it to maintain a singular focus on its core development and manufacturing expertise. The company's product pipeline targets various therapeutic areas, including autoimmune and eye disorders.

Recent filings

Filing Released Lang Actions
MANAGERS' TRANSACTIO NOTIFICATION
Director's Dealing Classification · 1% confidence The document is a formal notification of a transaction by a person discharging managerial responsibilities (PDMR) or a person closely associated with them. It explicitly follows the standard regulatory format for reporting insider dealings (often referred to as a PDMR notification or Form HOS-2). The content details the disposal of shares by an entity closely associated with the CEO/Chairman of Alvotech. This falls directly under the 'Director's Dealing' category.
2026-02-12 English
Alvotech tilkynnir um aukningu í fjölda eigin bréfa
Share Issue/Capital Change Classification · 1% confidence The document is an official announcement from Alvotech regarding the issuance of 12.5 million new shares, which are being acquired by a subsidiary as treasury shares. This directly relates to changes in the company's capital structure and share count. According to the provided definitions, 'Share Issue/Capital Change' (SHA) is the appropriate category for announcements regarding new share issues or capital changes, and 'Transaction in Own Shares' (POS) covers share buybacks or treasury share management. Given the primary focus is the issuance of new shares to increase treasury holdings, 'SHA' is the most accurate classification.
2026-02-11 Icelandic
Alvotech Announces Increase in Number of Own Shares
Share Issue/Capital Change Classification · 1% confidence The document details a specific corporate action involving the issuance of 12,500,000 new ordinary shares and the subsequent increase in the company's total share capital. It explicitly discusses the impact on treasury shares and the total number of issued shares. This falls directly under the category of share issuance and capital changes.
2026-02-11 English
Alvotech kynnir jákvæða niðurstöðu rannsóknar á lyfjahvörfum AVT80, fyrirhugaðrar hliðstæðu við líftæknilyfið Entyvio
Regulatory Filings Classification · 1% confidence The document is a press release from Alvotech announcing positive clinical trial results for its drug candidate AVT80. It details the study's success, the implications for future regulatory filings, and provides background on the company and the drug. It does not fit into specific financial reporting categories like 10-K or IR, nor is it a simple report publication announcement (RPA) as it contains substantive news content. Therefore, it is classified as a general regulatory announcement (RNS).
2026-02-05 Icelandic
Alvotech Announces Positive Top-Line Results from Pivotal Pharmacokinetic Study for Proposed Biosimilar to Entyvio®
Regulatory Filings Classification · 1% confidence The document is a press release issued by Alvotech announcing positive top-line results from a clinical study (pharmacokinetic study for AVT80). It follows the standard format of a corporate press release, providing details on the study, its significance, and forward-looking statements. Since it does not fit into specific categories like financial reports, dividend announcements, or governance filings, and is a general corporate announcement, it is classified as a Regulatory Filing (RNS).
2026-02-05 English
6-K Filing
Foreign Filer Report
2026-02-05 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.